Protheos, a leading player in the biotechnology sector, is headquartered in France and operates extensively across Europe. Founded in 2015, the company has rapidly established itself as a pioneer in the development of innovative biopharmaceutical solutions, focusing on advanced therapies and personalised medicine. Protheos is renowned for its unique approach to drug development, leveraging cutting-edge technologies to enhance therapeutic efficacy and patient outcomes. With a commitment to research and development, the company has achieved significant milestones, including collaborations with major pharmaceutical firms and successful clinical trials. As a trusted name in the industry, Protheos continues to push the boundaries of biotechnology, positioning itself at the forefront of medical advancements and contributing to the evolution of healthcare solutions.
How does Protheos's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Protheos's score of 26 is lower than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Protheos reported total carbon emissions of approximately 124,700 kg CO2e, with emissions distributed across various scopes: 1,100 kg CO2e from Scope 1, 1,800 kg CO2e from Scope 2, and a significant 121,800 kg CO2e from Scope 3. This data reflects a slight decrease from 2022, when total emissions were about 128,000 kg CO2e, with similar scope distributions. Protheos has set a near-term reduction target for Scope 2 emissions, aiming for a 20% decrease by 2028, projecting emissions to fall to approximately 1,200 kg CO2e. This commitment underscores the company's proactive approach to mitigating its carbon footprint. The emissions data is not cascaded from any parent organisation, indicating that Protheos independently reports its climate impact. The company continues to focus on enhancing its sustainability practices as part of its broader climate commitments.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Protheos has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
